Hemophilia

We recommend

Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF

4. 11. 2024 Source: Hemophilia

Níže citovaná studie fáze III hodnotila účinnost a bezpečnost 12měsíční profylaxe rekombinantním von Willebrandovým faktorem (rvWF) u 23 pacientů s těžkou von Willebrandovou chorobou (vWD), kteří byli dříve léčeni jen podle potřeby (při výskytu spontánního krvácení) nebo předtím užívali profylaxi vWF získaným z plazmy (pdvWF).

Smaller Volume and Faster Infusion Rate of aPCC: What Do Current Data Say About This Modification?

Podání infuze s koncentrátem aktivovaného protrombinového komplexu (aPCC) při standardizované…

6. 10. 2024 Source: Hemophilia

Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment

With the development of new treatment options for hemophilia, there has also been progress in…

10. 6. 2024 Source: Hemophilia

Articles on this topic

Rurioctocog alfa pegol in previously treated patients with severe hemophilia A: What findings did the long-term continuation study bring?

Rurioctocog alfa pegol (Adynovi) is a recombinant coagulation factor VIII modified by…

2. 11. 2020 Source: Hemophilia

medicina_budoucnost_krev_srazlivost_krevni_desticky

Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors

Activated prothrombin complex concentrates (aPCC) are essential drugs that not only allow the…

2. 11. 2020 Source: Hemophilia

ilustrační foto v tiskové kvalitě L 2356 x 1571

Observational Study of Pegylated rVIII Administration in Real Clinical Practice

A recently published article by American hematologists provided valuable information about the…

21. 9. 2020 Source: Hemophilia

Cost-effectiveness in Bleeding Control for Acquired Hemophilia A

A pharmacoeconomic analysis showed favorable cost-effectiveness of activated prothrombin…

18. 9. 2020 Source: Hemophilia

boty_nohy_chůze_běh_pohyb_sport_muž_procházka

Minimum and Optimal Factor Levels in Physically Active Hemophiliacs

Authors of a recently published study attempted to determine the value of minimum and optimal…

2. 7. 2020 Source: Hemophilia

Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy

New molecules in hemophilia therapy have raised many questions, including regarding the…

18. 3. 2020 Source: Hemophilia

Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia

Experience shows that monitoring joint changes, especially subclinical ones, is very necessary…

16. 3. 2020 Source: Hemophilia

Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A

With new treatment options for hemophilia A without inhibitors, the question of…

15. 1. 2020 Source: Hemophilia

Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?

The aging population of individuals with hemophilia brings new experiences and challenges,…

10. 1. 2020 Source: Hemophilia

1 2 3

E-courses on this topic

Authors: doc. MUDr. Zuzana Čermáková, Ph.D.

Course detail